[Hormonal therapy of the advanced breast cancer ].
In this review several possibilities of an individualized hormonal therapy of the advanced breast cancer are discussed. Tumors selected for hormonal therapy on the basis of a positive estrogen receptor respond to endocrine therapy at nearly twice the rate of those chosen by clinical criteria alone. The overall response can be predicted with an accuracy of about 75 per cent. Furthermore clinical tests like short time treatment with L-dopa or testosterone are liable for many subjective mistakes. If the multivalent analyse of various prognostic criteria will be better for predicting the mistakes. If the multivalent analyse of various prognostic criteria will be better for predicting the hormone sensitivity is up to now unknown. The paper gives several guides for the ablative and additive hormonal therapies.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000315:Adrenalectomy; D000328:Adult; D001943:Breast Neoplasms / Q000032:analysis / Q000556:secondary*; D002369:Castration; D045166:Estradiol Congeners / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007016:Hypophysectomy; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D045165:Testosterone Congeners / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D045166:Estradiol Congeners; D004965:Estrogen Antagonists; D006728:Hormones; D011960:Receptors, Estrogen; D045165:Testosterone Congeners
Hormontherapie des metastasierenden Mammakarzinoms.